<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy and lifestyle changes. Intravesical treatment of superficial bladder cancer with Еpirubicin or Bacillus Calmette-Guérin (BCG) is a continuation of surgical treatment to reduce or eliminate further recurrence.</p>
</abstract>

Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy and lifestyle changes. Intravesical treatment of superficial bladder cancer with Еpirubicin or Bacillus Calmette-Guérin (BCG) is a continuation of surgical treatment to reduce or eliminate further recurrence.

Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis

University Hospital “St. Marina” -Pleven Medical University - Pleven

Journal of Biomedical and Clinical Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery,...

Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis

Publié en ligne: 13 juil. 2022

Pages: 70 - 73

Reçu: 18 janv. 2022

Accepté: 11 mai 2022

DOI: https://doi.org/10.2478/jbcr-2022-0009

Mots clés
bladder cancer, intravesical therapy, epirubicin, BCG

© 2022 Nikolay I. Nikolov et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis

Publié en ligne: 13 juil. 2022

Pages: 70 - 73

Reçu: 18 janv. 2022

Accepté: 11 mai 2022

DOI: https://doi.org/10.2478/jbcr-2022-0009

Mots clésbladder cancer, intravesical therapy, epirubicin, BCG

© 2022 Nikolay I. Nikolov et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
bladder cancer, intravesical therapy, epirubicin, BCG